- Home
- NBY
NBY
NovaBay Pharmaceuticals Inc.
as 03-28-2025 4:00pm EST
Stocks
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | N/A | IPO Year: | 2007 |
| Target Price: | $0.85 | AVG Volume (30 days): | 51.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $9.10 | Next Earning Date: | 05-08-2025 |
| Revenue: | $13,844,000 | Revenue Growth: | 15.40% |
| Revenue Growth (this year): | -26.33% | Revenue Growth (next year): | 11.73% |
Latest NovaBay Pharmaceuticals Inc. News
NBY Breaking Stock News: Dive into NBY Ticker-Specific Updates for Smart Investing
Business Wire
24 days ago
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders
Business Wire
2 months ago
NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal
Zacks
3 months ago
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why
Business Wire
3 months ago
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
Business Wire
4 months ago
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting
Business Wire
4 months ago
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
Business Wire
4 months ago
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
Business Wire
5 months ago
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
Compare NBY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBY NovaBay Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.